<p>Sinobioway Medicine announced that its operating revenue in the first half of 2025 was 70.7715 million yuan, a year-on-year decrease of 66.42%. The net loss attributable to shareholders of the listed company was 67.3027 million yuan, compared to a net loss of 29.6149 million yuan in the same period last year. The company plans not to distribute cash dividends, not to issue bonus shares, and not to increase capital by converting reserves</p>

002581

<p>ST Sinobioway Medicine announced that in the first half of 2025, operating revenue was 70.7715 million yuan, a year-on-year decrease of 66.42%. The net loss attributable to shareholders of the listed company was 67.3027 million yuan, compared to a net loss of 29.6149 million yuan in the same period last year. The company plans not to distribute cash dividends, not to issue bonus shares, and not to increase capital using reserves</p>

Sinobioway Medicine: Net loss of 67.3027 million yuan in the first half of 2025